NO308600B1 - Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene - Google Patents

Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene

Info

Publication number
NO308600B1
NO308600B1 NO964093A NO964093A NO308600B1 NO 308600 B1 NO308600 B1 NO 308600B1 NO 964093 A NO964093 A NO 964093A NO 964093 A NO964093 A NO 964093A NO 308600 B1 NO308600 B1 NO 308600B1
Authority
NO
Norway
Prior art keywords
alkyl
opt
alkoxy
substd
cycloalkyl
Prior art date
Application number
NO964093A
Other languages
English (en)
Other versions
NO964093D0 (no
NO964093L (no
Inventor
Klaus Weidmann
Karl-Heinz Baringhaus
Georg Tschank
Martin Bickel
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19536263A external-priority patent/DE19536263A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO964093D0 publication Critical patent/NO964093D0/no
Publication of NO964093L publication Critical patent/NO964093L/no
Publication of NO308600B1 publication Critical patent/NO308600B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO964093A 1995-09-28 1996-09-27 Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene NO308600B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19536263A DE19536263A1 (de) 1995-09-28 1995-09-28 Substituierte Chinolin-2-carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19605170 1996-02-13

Publications (3)

Publication Number Publication Date
NO964093D0 NO964093D0 (no) 1996-09-27
NO964093L NO964093L (no) 1997-04-01
NO308600B1 true NO308600B1 (no) 2000-10-02

Family

ID=26019051

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964093A NO308600B1 (no) 1995-09-28 1996-09-27 Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene

Country Status (20)

Country Link
US (2) US5719164A (no)
EP (1) EP0765871B1 (no)
JP (1) JPH09124606A (no)
KR (1) KR970061869A (no)
CN (2) CN1120157C (no)
AT (1) ATE263155T1 (no)
AU (1) AU728208B2 (no)
CA (1) CA2186717A1 (no)
CZ (1) CZ283396A3 (no)
DE (1) DE59610950D1 (no)
ES (1) ES2215184T3 (no)
HU (1) HUP9602685A3 (no)
IL (2) IL135495A (no)
MX (1) MX9604378A (no)
MY (1) MY133647A (no)
NO (1) NO308600B1 (no)
NZ (1) NZ299455A (no)
PL (1) PL316321A1 (no)
SG (1) SG45503A1 (no)
SI (1) SI9600287A (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19650215A1 (de) * 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US20020198145A1 (en) * 1999-06-10 2002-12-26 Cognetix, Inc. MuO-conopeptides and their use as local anesthetics
JP4092203B2 (ja) * 2000-12-21 2008-05-28 ニトロメッド,インク. 新規のシクロオキシゲナーゼ2選択的阻害剤としての置換アリール化合物、組成物、および使用方法
WO2002074981A2 (en) * 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
CN1602360A (zh) * 2001-12-06 2005-03-30 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
CN1816527A (zh) 2003-06-06 2006-08-09 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
WO2005034929A2 (en) * 2003-10-10 2005-04-21 Fibrogen, Inc. Tissue remodeling and vascularization
EP1893186A2 (en) * 2005-06-06 2008-03-05 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
AU2006259352A1 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of HIF 1alfa modulators for treatment of cancer
ES2341489T3 (es) 2005-07-27 2010-06-21 F.Hoffmann-La Roche Ag Derivados de 4-ariloxi quinolina como moduladores de 5-ht6.
CA2634168C (en) * 2005-12-09 2013-04-23 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
CN101374815B (zh) * 2006-01-27 2013-07-17 菲布罗根有限公司 使低氧诱导因子(hif)稳定的氰基异喹啉化合物
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
US7625927B2 (en) * 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
PL2008460T3 (pl) * 2006-03-30 2017-10-31 Lg Electronics Inc Sposób i urządzenie do dekodowania/kodowania sygnału wideo
BRPI0710527B8 (pt) * 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
HUE041300T2 (hu) 2006-06-26 2019-05-28 Akebia Therapeutics Inc Prolilhidroxiláz inhibitorok és alkalmazási eljárások
ES2393326T3 (es) * 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
EP2111399A2 (en) * 2006-12-18 2009-10-28 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
US7569726B2 (en) * 2007-04-18 2009-08-04 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
CA2683956C (en) * 2007-04-18 2012-12-18 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
CA2685219C (en) * 2007-05-04 2012-06-19 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
ES2389063T3 (es) * 2007-05-04 2012-10-22 Amgen, Inc Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Hifヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
BR112012014180A2 (pt) 2009-12-17 2015-09-15 Merck Sharp & Dohme composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
EA026745B8 (ru) 2011-02-07 2022-01-31 Байоджен Ма Инк. Модуляторы s1p
NO2686520T3 (no) 2011-06-06 2018-03-17
AU2013229922B2 (en) 2012-03-09 2017-09-28 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as HIF hydroxylase inhibitors
LT2872488T (lt) 2012-07-16 2018-10-25 Fibrogen, Inc. Kristalinės prolilhidroksilazės inhibitoriaus formos
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
US9340511B2 (en) 2012-07-16 2016-05-17 Fibrogen, Inc. Process for making isoquinoline compounds
CN104768541B (zh) * 2012-07-27 2018-08-17 比奥根艾迪克Ma公司 Atx调节剂
RU2666144C2 (ru) 2013-01-24 2018-09-06 Фиброген, Инк. Кристаллические формы { [1-циано-5-(4-хлорофенокси)-4-гидроксиизохинолин-3-карбонил]-амино} -уксусной кислоты
NZ714963A (en) 2013-06-13 2020-07-31 Akebia Therapeutics Inc Compositions and methods for treating anemia
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
NZ773901A (en) 2015-04-01 2024-07-26 Akebia Therapeutics Inc Compositions and methods for treating anemia
AU2019265629B2 (en) 2018-05-09 2024-09-12 Akebia Therapeutics, Inc. Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid
MX2021005314A (es) 2018-11-09 2021-08-24 Vivace Therapeutics Inc Compuestos biciclicos.
EP3956033A4 (en) 2019-04-16 2023-01-11 Vivace Therapeutics, Inc. BICYCLIC LINKS
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015255A1 (de) * 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
EP0541042A1 (de) * 1991-11-05 1993-05-12 Hoechst Aktiengesellschaft Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4233124A1 (de) * 1992-10-02 1994-04-07 Hoechst Ag Acylsulfonamido- und Sulfonamidopyridin-2-carbonsäureester sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK122693D0 (da) * 1993-10-29 1993-10-29 Hempels Skibsfarve Fab J C Marin struktur
DE59401923D1 (de) * 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
DK0650961T3 (da) * 1993-11-02 1997-09-15 Hoechst Ag Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
CA2138929A1 (en) * 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
PL316321A1 (en) 1997-04-01
MX9604378A (es) 1997-03-29
HUP9602685A2 (hu) 1998-09-28
EP0765871A1 (de) 1997-04-02
IL135495A (en) 2002-12-01
NZ299455A (en) 1997-06-24
ATE263155T1 (de) 2004-04-15
CN1282737A (zh) 2001-02-07
HUP9602685A3 (en) 2001-04-28
EP0765871B1 (de) 2004-03-31
IL119302A0 (en) 1996-12-05
CN1154365A (zh) 1997-07-16
NO964093D0 (no) 1996-09-27
CA2186717A1 (en) 1997-03-29
SG45503A1 (en) 1998-01-16
HU9602685D0 (en) 1996-11-28
AU728208B2 (en) 2001-01-04
US5719164A (en) 1998-02-17
SI9600287A (en) 1997-04-30
KR970061869A (ko) 1997-09-12
CN1120157C (zh) 2003-09-03
ES2215184T3 (es) 2004-10-01
US5726305A (en) 1998-03-10
MY133647A (en) 2007-11-30
CZ283396A3 (en) 1997-04-16
AU6583896A (en) 1997-04-10
JPH09124606A (ja) 1997-05-13
DE59610950D1 (de) 2004-05-06
NO964093L (no) 1997-04-01

Similar Documents

Publication Publication Date Title
NO308600B1 (no) Substituerte chinolin-2-karboksylsyreamider, deres fremstilling og deres anvendelse for fremstilling av legemidler og farmasøytiske preparater, legemiddel inneholdende disse sÕvel som mellomprodukter til forbindelsene
MY128654A (en) Liquid pharmaceutical composition containing an erythropoietin derivative
DK436289D0 (da) Cycloalkyl-substituerede glutaramidderivater, farmaceutiske praeparater indeholdende disse forbindelser, forbindelserne til medicinsk anvendelse og deres anvendelse til fremstilling af laegemidler til behandling af hypertension, hjertesvigt eller renal insufficiens
DE69429708D1 (de) Galanthamin Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
IE881994L (en) Substituted azepines and pyrrolidines
ES2182454T3 (es) Derivados de amida y su uso terapeutico.
DK0667768T3 (da) Anvendelse af toremifen til behandling af SLE
PH24782A (en) Composition containing a penem or carbapenem antibiotic and the use of the same
IL105020A0 (en) Carbapenem derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
HUT34210A (en) Process for producing new cepheme-carboxylic acid derivatives and pharmaceutical compositions containing them as active ingredients
IL88921A0 (en) Anti-psychotic pharmaceutical compositions containing a certain imidazobenzodiazepine
NZ242351A (en) 3-aryl oxazolidinone derivatives, preparation and pharmaceutical compositions thereof
BR1100564A (pt) Formas cristalinas de mono-hidrato do cloridrato de endo-2,3-dihidro-n-(8-metil-8-azabiciclo[3.2.1]oct-3-il)-2 - -oxo-1h-benzimidazol-1-carboxamida e de mono-hidrato do cloridrato de endo-3-etil-2,3-di-hidro-n-(8-metil-8-azabiciclo[3.2.1]oc t-3-il)-2-oxo-1h-benzimidazol-1-carboxamida como antagonistas do 5-ht
DK165923C (da) 2,3-dihydro-1-(8-methyl-1,2,4-triazolo(4,3-b)pyridazin-6-yl)-4(1h)-pyridinon i praktisk taget ren form, fremgangsmaader til dens fremstilling, dens anvendelse som og til fremstilling af et laegemiddel samt farmaceutisk praeparat indeholdende den
MX9805321A (es) Tieno[2,3-b]pirazolo[3,4-d]piridin-3-onas para incrementar la eritropoyesis.
IE35218B1 (en) Improvements in or relating to azepine derivatives
ITTE930001A0 (it) Procedimento per l'arricchimento del tenore in zeoliti di sottoprodot-ti delle cave di blocchetti di "tufo litoide"
IT1233837B (it) Derivati diidropiridinici, loro preparazione e impieghi farmaceutici.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees